Philip Gotwals
Net worth: 81 999 $ as of 2026-06-29
Net worth: 81 999 $ as of 2026-06-29
Philip J.
Gotwals is currently an Independent Director at Capricor Therapeutics, Inc. since 2023 and an Independent Director at OmniAb, Inc. starting in 2025.
Formerly, Dr. Gotwals was Vice President-Business Development & Licensing at Novartis Institutes for Biomedical Research, Inc. from 2019 to 2023, Vice President-Program Management at Altus Pharmaceuticals, Inc. from 2006 to 2009, and Senior Director-Early Development at Biogen, Inc. from 2004 to 2006.
Education includes undergraduate studies at Amherst College and a doctorate from the University of California, Berkeley.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OMNIAB, INC. 0.02% | 2026-06-16 | 33,333 ( 0.02% ) | 81 999 $ | 2026-06-29 |
| 2026-02-27 | 0 ( -.--% ) | - $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| CAPRICOR THERAPEUTICS, INC. | Director/Board Member | 2023-07-20 |
| OMNIAB, INC. | Director/Board Member | 2025-04-17 |
| Companies | Position | End |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 2023-09-30 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapeutic products for gastrointestinal and metabolic diseases | Corporate Officer/Principal | 2008-12-31 |
| BIOGEN INC. | Corporate Officer/Principal | 2006-08-31 |
Redsky Partners LLC
Redsky Partners LLC Financial ConglomeratesFinance RedSky invests long/short with a growth bias without regard to market capitalization. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Redsky Partners LLC
Redsky Partners LLC Financial ConglomeratesFinance RedSky invests long/short with a growth bias without regard to market capitalization. | Finance |
Amherst College
Amherst College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapeutic products for gastrointestinal and metabolic diseases | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative products for the treatment of cardiovascular diseases | Health Technology |
OmniAb, Inc.
OmniAb, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
Select your edition
All financial news and data tailored to specific country editions